Tislelizumab NSCLC Inclusion Recommended for Dutch Health Package

Tislelizumab NSCLC Inclusion in Dutch Basic Package

Zorginstituut Nederland’s Tislelizumab NSCLC Inclusion Recommendation

Zorginstituut Nederland’s advisory report, dated February 4, 2026, recommends the conditional Tislelizumab NSCLC inclusion in the Dutch basic health insurance package for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) following prior platinum-based therapy. The primary finding is that tislelizumab (Tevimbra®) meets the criterion of “state of the science and practice,” demonstrating equivalent clinical value to standard PD-(L)1 inhibitors nivolumab and atezolizumab, based on indirect comparisons from phase 3 randomized controlled trials (RCTs). This recommendation is contingent on successful price negotiations ensuring tislelizumab’s net price does not exceed that of comparable PD-(L)1 inhibitors.

Matching Efficacy Against Nivolumab and Atezolizumab

Indirect comparisons from the RATIONALE-303 RCT (tislelizumab versus docetaxel) with nivolumab (CHECKMATE-017/057) and atezolizumab (OAK) trials reveal no clinically relevant differences in overall survival (OS), with hazard ratios (HR) of 0.66 (95% confidence interval [CI]: 0.56-0.79) for tislelizumab, 0.59-0.73 for nivolumab, and 0.73 (95% CI: 0.62-0.87) for atezolizumab, all versus docetaxel. Quality-of-life measures, assessed via instruments like EORTC QLQ-C30/LC13 and EQ-5D-5L, show stabilization or slight improvements across agents, with no meaningful disparities; for instance, tislelizumab yielded a +5.7-point difference in global health status at week 18 versus docetaxel (95% CI: 2.38-9.07, p=0.0008).

Safety profiles are comparable, with grade 3-5 adverse events at 14.4% for tislelizumab (risk ratio [RR] 0.21 versus docetaxel) aligning with 7-15% for nivolumab and atezolizumab (RR 0.12-0.35), and lower discontinuation rates than docetaxel across all. A 2025 network meta-analysis (NMA) by Girard et al. further supports these trends, confirming overlapping confidence intervals for OS and severe adverse events. These data substantiate tislelizumab’s parity, positioning it as a viable alternative despite limited real-world experience since its 2023 market entry, enabling Tislelizumab NSCLC inclusion on par with established options.

Indirect Comparisons Driving Package Criteria Success

Non-small cell lung cancer represents the most common lung cancer subtype, affecting over 10,000 patients annually in the Netherlands, predominantly aged 60+, with <10% five-year survival in metastatic cases. Standard second-line therapy for Eastern Cooperative Oncology Group (ECOG) performance status 0-1 patients post-platinum chemotherapy favors PD-(L)1 inhibitors (nivolumab, atezolizumab) per Dutch guidelines, reserved for those untreated with immunotherapy in first line. The evaluation adhered to Zorginstituut’s four package criteria—effectiveness, cost-effectiveness, necessity, and feasibility—consulting stakeholders, as detailed in their pakketadvies for tislelizumab in NSCLC. Effectiveness was affirmed via naïve indirect comparisons of mature OS data from open-label phase 3 RCTs (RATIONALE-303: n=805; others similarly powered), supplemented by subgroup analyses addressing the RATIONALE-303’s 80% Asian cohort, which showed consistent HRs (0.66 Asian, 0.73 European) mirroring nivolumab/atezolizumab patterns. Cost-effectiveness was not assessed due to equivalence; feasibility included a budget impact analysis estimating 31 patients in year 3 at €66,305 annual cost per patient, yielding €1.7 million macro-impact but €304,189 savings with substitution (68% pembrolizumab, 32% nivolumab at list prices). This methodological rigor supports the claim of equivalent value, excluding EGFR/ALK-mutated cases until targeted therapies precede.

Price Parity Shapes Reimbursement and Market Impact

The report’s emphasis on price parity post-negotiation highlights health economics priorities in value-based reimbursement, projecting low market penetration (2.5-7.5% over three years) amid dominant pembrolizumab use (65% of 412 annual second-line starters per 2022-2024 claims data). Implications include reinforcing cost-containment via therapeutic equivalence without added benefit, which may potentially averting incremental spending in a €1.7 million year-3 scenario while enabling substitution savings at list prices—though actual negotiated rates for comparators may elevate net impact.

Conditional listing incentivizes pricing alignment, aligning with Dutch sluis (gated funding) mechanisms for high-cost drugs and broader trends in PD-(L)1 competition, where patent expirations (e.g., pembrolizumab ~2028-2030) could further compress budgets. This validates indirect/NMA methodologies for real-world evidence generation, promoting efficient resource allocation without compromising survival gains over docetaxel, though uncertainties in ECOG >1 applicability and non-list pricing warrant post-launch monitoring. Overall, the advisory exemplifies balanced HEOR integration, fostering sustainable Tislelizumab NSCLC inclusion for ~31 patients annually while safeguarding the basic package’s fiscal integrity.